Breakfast Briefing Series, Jan 26th, 2017

Who's Who in 2017: A Rocky Road for Healthcare Investments?

JLabs Bay Area

in collaboration with

BioPharma Consortium

When:      Thursday, January 26th, 2017, 8:00-10:00 AM

Where:     JLABS @ SSF
                  329 Oyster Point Blvd - 3rd Floor
                  South San Francisco, CA

Register: (For BPC's 30% discount, enter "BioConsortium" in the Promotional Code field)

Pricing:   $12 | General Public ($8.40 with discount)
                $8 | Student/Academic ($5.60 with discount)
               $25 | Onsite

Speaker Bio:
Jon Norris is a managing director for SVB's Healthcare practice. Norris oversees business development efforts for banking and lending opportunities as well as spearheading strategic relationships with many healthcare venture capital firms. He also helps SVB Capital through sourcing and advising on direct equity co-investment and limited partnership allocations.
In addition, he has authored numerous thought leadership pieces examining the flow of capital into healthcare, including detailed analysis of venture-backed M&A and IPOs. Norris has more than thirteen years of banking experience working with life science companies and venture capital firms.
Norris earned a bachelor's degree in business administration from the University of California, Riverside and a juris doctorate from Santa Clara University.
About Jon
Norris spends most of his non-banking time with his family in Los Altos, attending and coaching many youth sports. An avid baseball fan, he still plays baseball in a men's baseball league in San Jose.

2016 has been another wild ride, with early surprises and a bumpy start. With 2016 in the review mirror, Jon Norris takes a look at - and makes sense of - the past trends to provide an informed look into 2017.

As the 2017 investment market takes shape, what can we expect for the IPO and M&A markets? Jon will share his expertise and provide insight into:

  • How the 2016 healthcare landscape compares to previous years
  • Current and total healthcare and sector investments
  • Which Biopharma indications attracted the most funds
  • Which venture firms are most active
  • Changes in the past crossover phenomenon
  • Exits: the trends in IPOs and M&A's

At the end of this talk you should be informed as to who is investing, and the type of deals and exits that are likely to be executed in 2017.

Register: (For BPC's 30% discount, enter "BioConsortium" in the Promotional Code field)